TY - JOUR
T1 - Prognostic value of lower tract urinary symptoms in clinically regional lymph node-positive prostate cancer
AU - BLAS, LEANDRO
AU - IEIRI, KOSUKE
AU - SHIOTA, MASAKI
AU - NAGAKAWA, SHOHEI
AU - TSUKAHARA, SHIGEHIRO
AU - MATSUMOTO, TAKASHI
AU - KASHIWAGI, EIJI
AU - TAKEUCHI, ARIO
AU - INOKUCHI, JUNICHI
AU - SHIGA, KEN ICHIRO
AU - YOKOMIZO, AKIRA
AU - ETO, MASATOSHI
N1 - Publisher Copyright:
© 2021 International Institute of Anticancer Research. All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - Background/Aim: To explore the prognostic value of lower urinary tract symptoms (LUTS) in patients with newly diagnosed regional lymph node-positive prostate cancer. Patients and Methods: The prognostic value of LUTS for progression-free (PFS) and overall (OS) survival, as well as the differential prognostic impact of radiotherapy by LUTS was investigated. Results: Univariate Cox-model analysis showed a statistically significantly increased hazard risk for PFS and OS for men with International Prostate Symptom Score (IPSS)≥19 and Overactive Bladder Symptom Score (OABSS) ≥8 at diagnosis. Patients with lower IPSS had a better PFS at 5 years (70.0% vs. 51.9%, p=0.027) and OS at 5 year (89.3% vs. 73.6%, p=0.016). Similarly, a lower OABSS was associated with greater PFS at 5 years (67.4% vs. 23.4%, p<0.001) and OS at 5 years (85.3% vs. 57.1%, p=0.012). Conclusion: IPSS and OABSS were prognostic for PFS and OS in patients with regional lymph node-metastatic prostate cancer.
AB - Background/Aim: To explore the prognostic value of lower urinary tract symptoms (LUTS) in patients with newly diagnosed regional lymph node-positive prostate cancer. Patients and Methods: The prognostic value of LUTS for progression-free (PFS) and overall (OS) survival, as well as the differential prognostic impact of radiotherapy by LUTS was investigated. Results: Univariate Cox-model analysis showed a statistically significantly increased hazard risk for PFS and OS for men with International Prostate Symptom Score (IPSS)≥19 and Overactive Bladder Symptom Score (OABSS) ≥8 at diagnosis. Patients with lower IPSS had a better PFS at 5 years (70.0% vs. 51.9%, p=0.027) and OS at 5 year (89.3% vs. 73.6%, p=0.016). Similarly, a lower OABSS was associated with greater PFS at 5 years (67.4% vs. 23.4%, p<0.001) and OS at 5 years (85.3% vs. 57.1%, p=0.012). Conclusion: IPSS and OABSS were prognostic for PFS and OS in patients with regional lymph node-metastatic prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=85118871784&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118871784&partnerID=8YFLogxK
U2 - 10.21873/anticanres.15373
DO - 10.21873/anticanres.15373
M3 - Article
C2 - 34732430
AN - SCOPUS:85118871784
SN - 0250-7005
VL - 41
SP - 5593
EP - 5598
JO - Anticancer research
JF - Anticancer research
IS - 11
ER -
